Oropharyngeal Candida colonization in human immunodeficiency virus infected patients

APMIS

Volumn 121, Issue 5, 2013, Pages 375-402

  Li, Xiaoxu ^a   Lei, Lei ^a   Tan, Dan ^a   Jiang, Lu ^a   Zeng, Xin ^a   Dan, Hongxia ^a   Liao, Ga ^a   Chen, Qianming ^a  

^a SICHUAN UNIVERSITY   (China)

Author keywords

Candida carriage; Candida colonization; Human immunodeficiency virus; Oropharyngeal candidiasis

Indexed keywords

ANTIBIOTIC AGENT; ANTIFUNGAL AGENT; ANTIRETROVIRUS AGENT;

ANTIBIOTIC THERAPY; ASYMPTOMATIC DISEASE; CANDIDA; CD4 LYMPHOCYTE COUNT; CELL LEVEL; FUNGAL COLONIZATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MOUTH CAVITY; MOUTH HYGIENE; OROPHARYNX CANDIDIASIS; PREVALENCE; PRIORITY JOURNAL; REVIEW; SMOKING; THRUSH; VIRUS LOAD;

AIDS-RELATED OPPORTUNISTIC INFECTIONS; CANDIDA; CANDIDIASIS, ORAL; CD4-POSITIVE T-LYMPHOCYTES; HIV; HIV INFECTIONS; HUMANS; IMMUNITY, MUCOSAL; MOUTH MUCOSA; OROPHARYNX; RNA, VIRAL;

EID: 84876954734     PISSN: 09034641     EISSN: 16000463     Source Type: Journal    
DOI: 10.1111/apm.12006     Document Type: Review

References (134)

1. Kaviarasan PK, Thappa DM, Jaisankar TJ, Sujatha S. Candidiasis in HIV-infected patients: a clinical and microbiological study. Natl Med J India 2002;15:51-2.
2. Blignaut E. Oral candidiasis and oral yeast carriage among institutionalised South African paediatric HIV/AIDS patients. Mycopathologia 2007;163:67-73.
3. Bravo IM, Correnti M, Escalona L, Perrone M, Brito A, Tovar V, et al. Prevalence of oral lesions in HIV patients related to CD4 cell count and viral load in a Venezuelan population. Med Oral Patol Oral Cir Bucal 2006;11:E33-9.
4. Chakraborty N, Mukherjee A, Santra S, Sarkar RN, Banerjee D, Guha SK, et al. Current trends of opportunistic infections among HIV-seropositive patients from Eastern India. Jpn J Infect Dis 2008;61:49-53.
5. Blignaut E, Patton LL, Nittayananta W, Ramirez-Amador V, Ranganathan K, Chattopadhyay A. (A3) HIV Phenotypes, oral lesions, and management of HIV-related disease. Adv Dent Res 2006;19:122-9.
6. Lattif AA, Banerjee U, Prasad R, Biswas A, Wig N, Sharma N, et al. Susceptibility pattern and molecular type of species-specific Candida in oropharyngeal lesions of Indian human immunodeficiency virus-positive patients. J Clin Microbiol 2004;42:1260-2.
7. Sharma G, Pai KM, Suhas S, Ramapuram JT, Doshi D, Anup N. Oral manifestations in HIV/AIDS infected patients from India. Oral Dis 2006;12:537-42.
8. Selwyn PA, Alcabes P, Hartel D, Buono D, Schoenbaum EE, Klein RS, et al. Clinical manifestations and predictors of disease progression in drug users with human immunodeficiency virus infection. N Engl J Med 1992;327:1697-703.
9. Patton LL. Sensitivity, specificity, and positive predictive value of oral opportunistic infections in adults with HIV/AIDS as markers of immune suppression and viral burden. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2000;90:182-8.
10. Samaranayake L. Commensal oral Candida in Asian cohorts. Int J Oral Sci 2009;1:2-5.
11. Vargas K, Messer SA, Pfaller M, Lockhart SR, Stapleton JT, Hellstein J, et al. Elevated phenotypic switching and drug resistance of Candida albicans from human immunodeficiency virus-positive individuals prior to first thrush episode. J Clin Microbiol 2000;38:3595-607.
12. Torssander J, Morfeldt-Manson L, Biberfeld G, Karlsson A, Putkonen PO, Wasserman J. Oral Candida albicans in HIV infection. Scand J Infect Dis 1987;19:291-5.
13. Syrjanen S, Valle SL, Antonen J, Suni J, Saxinger C, Krohn K, et al. Oral Candidal infection as a sign of HIV infection in homosexual men. Oral Surg Oral Med Oral Pathol 1988;65:36-40.
14. Tylenda CA, Larsen J, Yeh CK, Lane HC, Fox PC. High levels of oral yeasts in early HIV-1 infection. J Oral Pathol Med 1989;18:520-4.
15. Franker CK, Lucartorto FM, Johnson BS, Jacobson JJ. Characterization of the mycoflora from oral mucosal surfaces of some HIV-infected patients. Oral Surg Oral Med Oral Pathol 1990;69:683-7.
16. Schmidt-Westhausen A, Schiller RA, Pohle HD, Reichart PA. Oral Candida and Enterobacteriaceae in HIV-1 infection: correlation with clinical candidiasis and antimy-cotic therapy. J Oral Pathol Med 1991;20:467-72.
17. De Bernardis F, Boccanera M, Rainaldi L, Guerra CE, Quinti I, Cassone A. The secretion of aspartyl proteinase, a virulence enzyme, by isolates of Candida albicans from the oral cavity of HIV-infected subjects. Eur J Epidemiol 1992;8:362-7.
18. Felix DH, Wray D. The prevalence of oral candidiasis in HIV-infected individuals and dental attenders in Edinburgh. J Oral Pathol Med 1993;22:418-20.
19. Hauman CH, Thompson IO, Theunissen F, Wolfaardt P. Oral carriage of Candida in healthy and HIV-seropositive persons. Oral Surg Oral Med Oral Pathol 1993;76:570-2.
20. Sangeorzan JA, Bradley SF, He X, Zarins LT, Ridenour GL, Tiballi RN, et al. Epidemiology of oral candidiasis in HIV-infected patients: colonization, infection, treatment, and emergence of fluconazole resistance. Am J Med 1994;97:339-46.
21. Chave JP, Durussel C, Glauser MP, Bille J. Asymptomatic oral yeast carriage in HIV-infected patients: frequency and fluconazole susceptibility profile. Clin Microbiol Infect 1996;1:249-52.
22. Martins MD, Lozano-Chiu M, Rex JH. Point prevalence of oropharyngeal carriage of fluconazole-resistant Candida in human immunodeficiency virus-infected patients. Clin Infect Dis 1997;25:843-6.
23. Schoofs AG, Odds FC, Colebunders R, Ieven M, Goossens H. Cross-sectional study of oral Candida carriage in a human immunodeficiency virus (HIV)-seropositive population: predisposing factors, epidemiology and antifungal susceptibility. Mycoses 1998;41:203-11.
24. Schuman P, Sobel JD, Ohmit SE, Mayer KH, Carpenter CC, Rompalo A, et al. Mucosal Candidal colonization and candidiasis in women with or at risk for human immunodeficiency virus infection. HIV Epidemiology Research Study (HERS) Group. Clin Infect Dis 1998;27:1161-7.
25. Teanpaisan R, Nittayananta W. Prevalence of Candida species in AIDS patients and HIV-free subjects in Thailand. J Oral Pathol Med 1998;27:4-7.
26. Gottfredsson M, Cox GM, Indridason OS, de Almeida GM, Heald AE, Perfect JR. Association of plasma levels of human immunodeficiency virus type 1 RNA and oropharyngeal Candida colonization. J Infect Dis 1999;180:534-7.
27. Ruhnke M, Grosch-Worner I, Lischewski A, Neubauer A, Steinmuller A, Trautmann M, et al. Genotypic relatedness of yeast isolates from women infected with human immunodeficiency virus and their children. Mycoses 1999;42:385-94.
28. Xu J, Boyd CM, Livingston E, Meyer W, Madden JF, Mitchell TG. Species and genotypic diversities and similarities of pathogenic yeasts colonizing women. J Clin Microbiol 1999;37:3835-43.
29. Tsang CS, Samaranayake LP. Oral yeasts and coliforms in HIV-infected individuals in Hong Kong. Mycoses 2000;43:303-8.
30. Nittayananta W, Jealae S, Winn T. Oral Candida in HIV-infected heterosexuals and intravenous drug users in Thailand. J Oral Pathol Med 2001;30:347-54.
31. Barchiesi F, Maracci M, Radi B, Arzeni D, Baldassarri I, Giacometti A, et al. Point prevalence, microbiology and fluconazole susceptibility patterns of yeast isolates colonizing the oral cavities of HIV-infected patients in the era of highly active antiretroviral therapy. J Antimicrob Chemother 2002;50:999-1002.
32. Campisi G, Pizzo G, Milici ME, Mancuso S, Margiotta V. Candidal carriage in the oral cavity of human immunodeficiency virus-infected subjects. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2002;93:281-6.
33. Gugnani HC, Becker K, Fegeler W, Basu S, Chattopadhya D, Baveja U, et al. Oropharyngeal carriage of Candida species in HIV-infected patients in India. Mycoses 2003;46:299-306.
34. Faggi E, Pini G, Campisi E, Martinelli C, Difonzo E. Detection of Candida dubliniensis in oropharyngeal samples from human immunodeficiency virus infected and non-infected patients and in a yeast culture collection. Mycoses 2005;48:211-5.
35. Binolfi A, Biasoli MS, Luque AG, Tosello ME, Magaro HM. High prevalence of oral colonization by Candida dubliniensis in HIV-positive patients in Argentina. Med Mycol 2005;43:431-7.
36. Hung CC, Yang YL, Lauderdale TL, McDonald LC, Hsiao CF, Cheng HH, et al. Colonization of human immunodeficiency virus-infected outpatients in Taiwan with Candida species. J Clin Microbiol 2005;43:1600-3.
37. Sanchez-Vargas LO, Ortiz-Lopez NG, Villar M, Moragues MD, Aguirre JM, Cashat-Cruz M, et al. Point prevalence, microbiology and antifungal susceptibility patterns of oral Candida isolates colonizing or infecting Mexican HIV/AIDS patients and healthy persons. Rev Iberoam Micol 2005;22:83-92.
38. Costa CR, Cohen AJ, Fernandes OF, Miranda KC, Passos XS, Souza LK, et al. Asymptomatic oral carriage of Candida species in HIV-infected patients in the highly active antiretroviral therapy era. Rev Inst Med Trop Sao Paulo 2006;48:257-61.
39. Liu X, Liu H, Guo Z, Luan W. Association of asymptomatic oral candidal carriage, oral candidiasis and CD4 lymphocyte count in HIV-positive patients in China. Oral Dis 2006;12:41-4.
40. Bauerle M, Schroppel K, Taylor B, Bergmann S, Schmitt-Haendle M, Harrer T. Analysis of the Candida albicans - specific T-cell response and oropharyngeal Candida colonization in a cohort of HIV-1-infected patients. Eur J Med Res 2006;11:479-84.
41. Patel M, Shackleton JT, Coogan MM. Effect of antifungal treatment on the prevalence of yeasts in HIV-infected subjects. J Med Microbiol 2006;55(Pt 9):1279-84.
42. Erkose G, Erturan Z. Oral Candida colonization of human immunodeficiency virus infected subjects in Turkey and its relation with viral load and CD4 + T-lymphocyte count. Mycoses 2007;50:485-90.
43. Luque AG, Biasoli MS, Tosello ME, Binolfi A, Lupo S, Magaro HM. Oral yeast carriage in HIV-infected and non-infected populations in Rosario, Argentina. Mycoses 2009;52:53-9.
44. Girish KCP, Menon T, Rajasekaran S, Sekar B, Prabu D. Carriage of Candida species in oral cavities of HIV infected patients in South India. Mycoses 2009;52:44-8.
45. Baradkar VP, Kumar S. Species identification of Candida isolates obtained from oral lesions of HIV infected patients. Indian J Dermatol 2009;54:385-6.
46. Jainkittivong A, Lin AL, Johnson DA, Langlais RP, Yeh CK. Salivary secretion, mucin concentrations and Candida carriage in HIV-infected patients. Oral Dis 2009;15:229-34.
47. Delgado AC, De Jesus Pedro R, Aoki FH, Resende MR, Trabasso P, Colombo AL, et al. Clinical and microbiological assessment of patients with a long-term diagnosis of human immunodeficiency virus infection and Candida oral colonization. Clin Microbiol Infect 2009;15:364-71.
48. Pignato S, Salvo S, Coniglio MA, Marranzano M, Faro G, Giammanco G. Persistent oral and urinary Candida spp. carriage in Italian HIV-seropositive asymptomatic subjects. J Prev Med Hyg 2009;50:232-5.
49. Back-Brito GN, Mota AJ, Vasconcellos TC, Querido SM, Jorge AO, Reis AS, et al. Frequency of Candida spp. in the oral cavity of Brazilian HIV-positive patients and correlation with CD4 cell counts and viral load. Mycopathologia 2009;167:81-7.
50. Badiee P, Alborzi A, Davarpanah MA, Shakiba E. Distributions and antifungal susceptibility of Candida species from mucosal sites in HIV positive patients. Arch Iran Med 2010;13:282-7.
51. Mane A, Panchvalli S, Bembalkar S, Risbud A. Species distribution & antifungal susceptibility of oral Candida colonising or infecting HIV infected individuals. Indian J Med Res 2010;131:836-8.
52. Wu CJ, Lee HC, Yang YL, Chang CM, Chen HT, Lin CC, et al. Oropharyngeal yeast colonization in HIV-infected outpatients in southern Taiwan: CD4 count, efavirenz therapy and intravenous drug use matter. Clin Microbiol Infect 2012;18:485-90.
53. Kantheti LP, Reddy B, Ravikumar S, Ch A, Chandrasekhar P, Rajeswari MR. Isolation, identification, and carriage of Candidal species in PHLAs and their correlation with immunological status in cases with and without HAART. J Oral Maxillofac Pathol 2012;16:38-44.
54. Junqueira JC, Vilela SF, Rossoni RD, Barbosa JO, Costa AC, Rasteiro VM, et al. Oral colonization by yeasts in HIV-positive patients in Brazil. Rev Inst Med Trop Sao Paulo 2012;54:17-24.
55. Fong IW, Laurel M, Burford-Mason A. Asymptomatic oral carriage of Candida albicans in patients with HIV infection. Clin Invest Med 1997;20:85-93.
56. Schmidt-Westhausen AM, Bendick C, Reichart PA, Samaranayake LP. Oral candidosis and associated Candida species in HIV-infected Cambodians exposed to antimycotics. Mycoses 2004;47:435-41.
57. Vargas KG, Joly S. Carriage frequency, intensity of carriage, and strains of oral yeast species vary in the progression to oral candidiasis in human immunodeficiency virus-positive individuals. J Clin Microbiol 2002;40:341-50.
58. Sant'Ana Pde L, Milan EP, Martinez R, Queiroz-Telles F, Ferreira MS, Alcantara AP, et al. Multicenter Brazilian study of oral Candida species isolated from AIDS patients. Mem Inst Oswaldo Cruz 2002;97:253-7.
59. Melo NR, Taguchi H, Jorge J, Pedro RJ, Almeida OP, Fukushima K, et al. Oral Candida flora from Brazilian human immunodeficiency virus-infected patients in the highly active antiretroviral therapy era. Mem Inst Oswaldo Cruz 2004;99:425-31.
60. Migliorati CA, Birman EG, Cury AE. Oropharyngeal candidiasis in HIV-infected patients under treatment with protease inhibitors. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2004;98:301-10.
61. Hamza OJ, Matee MI, Moshi MJ, Simon EN, Mugusi F, Mikx FH, et al. Species distribution and in vitro antifungal susceptibility of oral yeast isolates from Tanzanian HIV-infected patients with primary and recurrent oropharyngeal candidiasis. BMC Microbiol 2008;8:135.
62. Maninder J, Usha A. Isolation, characterization and antifungal susceptibility pattern of Candida species causing oropharyngeal candidiasis in HIV positive patients. J Commun Dis 2008;40:177-81.
63. Yang YL, Hung CC, Wang AH, Tseng FC, Leaw SN, Tseng YT, et al. Oropharyngeal colonization of HIV-infected outpatients in Taiwan by yeast pathogens. J Clin Microbiol 2010;48:2609-12.
64. Nweze EI, Ogbonnaya UL. Oral Candida isolates among HIV-infected subjects in Nigeria. J Microbiol Immunol Infect 2011;44:172-7.
65. Agwu E, Ihongbe JC, McManus BA, Moran GP, Coleman DC, Sullivan DJ. Distribution of yeast species associated with oral lesions in HIV-infected patients in Southwest Uganda. Med Mycol 2012;50:276-80.
66. Byadarahally Raju S, Rajappa S. Isolation and identification of candida from the oral cavity. ISRN Dent 2011;2011:487921.
67. Shin ES, Chung SC, Kim YK, Lee SW, Kho HS. The relationship between oral Candida carriage and the secretor status of bloodgroup antigens in saliva. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2003;96:48-53.
68. Martins MD, Lozano-Chiu M, Rex JH. Declining rates of oropharyngeal candidiasis and carriage of Candida albicans associated with trends toward reduced rates of carriage of fluconazole-resistant C. albicans in human immunodeficiency virus-infected patients. Clin Infect Dis 1998;27:1291-4.
69. Sullivan DJ, Westerneng TJ, Haynes KA, Bennett DE, Coleman DC. Candida dubliniensis sp. nov.: phenotypic and molecular characterization of a novel species associated with oral candidosis in HIV-infected individuals. Microbiology 1995;141(Pt 7):1507-21.
70. Cartledge JD, Midgley J, Gazzard BG. Non-albicans oral candidosis in HIV-positive patients. J Antimicrob Chemother 1999;43:419-22.
71. Sobel JD, Ohmit SE, Schuman P, Klein RS, Mayer K, Duerr A, et al. The evolution of Candida species and fluconazole susceptibility among oral and vaginal isolates recovered from human immunodeficiency virus (HIV)-seropositive and at-risk HIV-seronegative women. J Infect Dis 2000;183:286-93.
72. Nguyen MH, Peacock JE Jr, Morris AJ, Tanner DC, Nguyen ML, Snydman, et al. The changing face of candidemia: emergence of non-Candida albicans species and antifungal resistance. Am J Med 1996;100:617-23.
73. Arribas JR, Hernandez-Albujar S, Gonzalez-Garcia JJ, et al. Impact of protease inhibitor therapy on HIV-related oropharyngeal candidiasis. AIDS 2000;14:979-85.
74. Sanchez-Vargas LO, Ortiz-Lopez NG, Villar M, Moragues MD, Aguirre JM, Cashat-Cruz M, et al. Oral Candida isolates colonizing or infecting human immunodeficiency virus-infected and healthy persons in Mexico. J Clin Microbiol 2005;43:4159-62.
75. Chakrabarti A, Ghosh A, Batra R, Kaushal A, Roy P, Singh H. Antifungal susceptibility pattern of non-albicans Candida species & distribution of species isolated from Candidaemia cases over a 5 year period. Indian J Med Res 1996;104:171-6.
76. Colombo AL, Nakagawa Z, Valdetaro F, Branchini ML, Kussano EJ, Nucci M. Susceptibility profile of 200 bloodstream isolates of Candida spp. collected from Brazilian tertiary care hospitals. Med Mycol 2003;41:235-9.
77. Cuenca-Estrella M, Rodero L, Garcia-Effron G, Rodriguez-Tudela JL. Antifungal susceptibilities of Candida spp. isolated from blood in Spain and Argentina, 1996-1999. J Antimicrob Chemother 2002;49:981-7.
78. Diekema DJ, Messer SA, Brueggemann AB, Coffman SL, Doern GV, Herwaldt LA, et al. Epidemiology of candidemia: 3-year results from the emerging infections and the epidemiology of Iowa organisms study. J Clin Microbiol 2002;40:1298-302.
79. Foongladda S, Sakulmaiwatana P, Petlum P, Vanprapar N. Candida species, genotypes and antifungal susceptibility of Candida isolates from blood samples of patients at the largest tertiary care hospital in Thailand during 1999-2002. J Med Assoc Thai 2004;87:92-9.
80. Godoy H, Reichart PA. Oral manifestations of paracoccidioidomycosis. Report of 21 cases from Argentina. Mycoses 2003;46:412-7.
81. Marco F, Danes C, Almela M, Jurado A, Mensa J, de la Bellacasa JP, et al. Trends in frequency and in vitro susceptibilities to antifungal agents, including voriconazole and anidulafungin, of Candida bloodstream isolates. Results from a six-year study (1996-2001). Diagn Microbiol Infect Dis 2003;46:259-64.
82. Law D, Moore CB, Wardle HM, Ganguli LA, Keaney MG, Denning DW. High prevalence of antifungal resistance in Candida spp. from patients with AIDS. J Antimicrob Chemother 1994;34:659-68.
83. McCullough MJ, Jorge JJ, Lejbkowicz F, Lefler E, Nassar F, Clemons KV, et al. Genotypic differences of Candida albicans and C. dubliniensis isolates related to ethnic/racial differences within the same geographic area. Mycopathologia 2004;158:39-41.
84. Dronda F, Alonso-Sanz M, Laguna F, Chaves F, Martinez-Suarez JV, Rodriguez-Tudela JL, et al. Mixed oropharyngeal candidiasis due to Candida albicans and non-albicans Candida strains in HIV-infected patients. Eur J Clin Microbiol Infect Dis 1996;15:446-52.
85. Pietrella D, Monari C, Retini C, Palazzetti B, Bistoni F, Vecchiarelli A. Human immunodeficiency virus type 1 envelope protein gp120 impairs intracellular antifungal mechanisms in human monocytes. J Infect Dis 1998;177:347-54.
86. Gruber A, Lukasser-Vogl E, Borg-von ZM, Dierich MP, Wurzner R. Human immunodeficiency virus type 1 gp160 and gp41 binding to Candida albicans selectively enhances candidal virulence in vitro. J Infect Dis 1998;177:1057-63.
87. Lewandowski D, Marquis M, Aumont F, Lussier-Morin AC, Raymond M, Senechal S, et al. Altered CD4 + T cell phenotype and function determine the susceptibility to mucosal candidiasis in transgenic mice expressing HIV-1. J Immunol 2006;177:479-91.
88. Ohmit SE, Sobel JD, Schuman P, Duerr A, Mayer K, Rompalo A, et al. Longitudinal study of mucosal Candida species colonization and candidiasis among human immunodeficiency virus (HIV)-seropositive and at-risk HIV-seronegative women. J Infect Dis 2003;188:118-27.
89. Coogan MM, Sweet SP, Challacombe SJ. Immunoglobulin A (IgA), IgA1, and IgA2 antibodies to Candida albicans in whole and parotid saliva in human immunodeficiency virus infection and AIDS. Infect Immun 1994;62:892-6.
90. Cutler CW, Jotwani R. Oral mucosal expression of HIV-1 receptors, co-receptors, and alpha-defensins: tableau of resistance or susceptibility to HIV infection. Adv Dent Res 2006;19:49-51.
91. Campo J, Del RJ, Castilla J, Garcia S, Rodriguez C, Bascones A. Oral candidiasis as a clinical marker related to viral load, CD4 lymphocyte count and CD4 lymphocyte percentage in HIV-infected patients. J Oral Pathol Med 2002;31:5-10.
92. Margiotta V, Campisi G, Mancuso S, Accurso V, Abbadessa V. HIV infection: oral lesions, CD4 + cell count and viral load in an Italian study population. J Oral Pathol Med 1999;28:173-7.
93. Ramirez-Amador V, Esquivel-Pedraza L, Sierra-Madero J, Anaya-Saavedra G, Gonzalez-Ramirez I, Ponce-de-Leon S. The Changing Clinical Spectrum of Human Immuno-deficiency Virus (HIV)-Related Oral Lesions in 1, 000 Consecutive Patients: a 12-Year Study in a Referral Center in Mexico. Medicine (Baltimore) 2003;82:39-50.
94. Saha K, Firdaus R, Santra P, Pal J, Roy A, Bhattacharya MK, et al. Recent pattern of Co-infection amongst HIV seropositive individuals in tertiary care hospital. Kolkata. Virol J 2011;8:116.
95. Rabeneck L, Crane MM, Risser JM, Lacke CE, Wray NP. A simple clinical staging system that predicts progression to AIDS using CD4 count, oral thrush, and night sweats. J Gen Intern Med 1993;8:5-9.
96. Nielsen H, Bentsen KD, Hojtved L, Willemoes EH, Scheutz F, Schiodt M, et al. Oral candidiasis and immune status of HIV-infected patients. J Oral Pathol Med 1994;23:140-3.
97. Greenspan D, Komaroff E, Redford M, Phelan JA, Navazesh M, Alves ME, et al. Oral mucosal lesions and HIV viral load in the Women's Interagency HIV Study (WIHS). J Acquir Immune Defic Syndr 2000;25:44-50.
98. Gasparin AB, Ferreira FV, Danesi CC, Mendoza-Sassi RA, Silveira J, Martinez AM, et al. Prevalence of oral lesions in persons with HIV and associated factors in a southern Brazilian city. Cad Saude Publica 2009;25:1307-15.
99. Feigal DW, Katz MH, Greenspan D, Westenhouse J, Winkelstein W Jr, Lang W, et al. The prevalence of oral lesions in HIV-infected homosexual and bisexual men: three San Francisco epidemiological cohorts. AIDS 1991;5:519-25.
100. Kolokotronis A, Kioses V, Antoniades D, Mandraveli K, Doutsos I, Papanayotou P. Immunologic status in patients infected with HIV with oral candidiasis and hairy leukoplakia. Oral Surg Oral Med Oral Pathol 1994;78:41-6.
101. Leigh JE, Barousse M, Swoboda RK, Myers T, Hager S, Wolf NA, et al. Candida-specific systemic cell-mediated immune reactivities in human immunodeficiency virus-positive persons with mucosal candidiasis. J Infect Dis 2001;183:277-85.
102. Witzel AL, Silveira FR, Pires MF, Lotufo MA. Oral candidiasis in HIV+ patients under treatment with protease inhibitors. Braz Oral Res 2008;22:371-7.
103. Fidel PL Jr. Candida-host interactions in HIV disease: relationships in oropharyngeal candidiasis. Adv Dent Res 2006;19:80-4.
104. Capoluongo E, Moretto D, Giglio A, Belardi M, Prignano G, Crescimbeni E, et al. Heterogeneity of oral isolates of Candida albicans in HIV-positive patients: correlation between candidal carriage, karyotype and disease stage. J Med Microbiol 2000;49:985-91.
105. Bard E, Laibe S, Clair S, Biichle S, Millon L, Drobacheff C, et al. Nonspecific secretory immunity in HIV-infected patients with oral candidiasis. J Acquir Immune Defic Syndr 2002;31:276-84.
106. Bergmeier LA, Lehner T. Innate and adaptive mucosal immunity in protection against HIV infection. Adv Dent Res 2006;19:21-8.
107. Chattopadhyay A, Gray LR, Patton LL, Caplan DJ, Slade GD, Tien HC, et al. Salivary secretory leukocyte protease inhibitor and oral candidiasis in human immunodeficiency virus type 1-infected persons. Infect Immun 2004;72:1956-63.
108. Teleshova N, Kenney J, Robbiani M. Dendritic cells and HIV infection: activating dendritic cells to boost immunity. Adv Dent Res 2006;19:36-41.
109. Steele C, Leigh J, Swoboda R, Fidel PL Jr. Growth inhibition of Candida by human oral epithelial cells. J Infect Dis 2000;182:1479-85.
110. Mane A, Gaikwad S, Bembalkar S, Risbud A. Increased expression of virulence attributes in oral Candida albicans isolates from HIV -positive individuals. J Med Microbiol 2011;61:285-90.
111. Meiller TF, Hube B, Schild L, Shirtliff ME, Scheper MA, Winkler R, et al. A novel immune evasion strategy of candida albicans: proteolytic cleavage of a salivary antimicrobial peptide. PLoS ONE 2009;4:e5039.
112. Ollert MW, Wende C, Gorlich M, McMullan-Vogel CG, Borg-von Zepelin M, Vogel CW, et al. Increased expression of Candida albicans secretory proteinase, a putative virulence factor, in isolates from human immunodeficiency virus-positive patients. J Clin Microbiol 1995;33:2543-9.
113. Ripeau JS, Fiorillo M, Aumont F, Belhumeur P, de Repentigny L. Evidence for differential expression of candida albicans virulence genes during oral infection in intact and human immunodeficiency virus type 1-transgenic mice. J Infect Dis 2002;185:1094-102.
114. Wurzner R, Gruber A, Stoiber H, Spruth M, Chen YH, Lukasser-Vogl E, et al. Human immunodeficiency virus type 1 gp41 binds to Candida albicans via complement C3-like regions. J Infect Dis 1997;176:492-8.
115. Sanchez-Vargas LO, Perez-Rios P, Romo-Garcia J, Corona-Izquierdo FP, Hidalgo-Loperena H, Franco-Martinez F. Salivary pH and culture determinations in HIV infected and non-HIV infected patients with oral candidosis. Rev Iberoam Micol 2002;19:155-60.
116. Sweet SP, Cookson S, Challacombe SJ. Candida albicans isolates from HIV-infected and AIDS patients exhibit enhanced adherence to epithelial cells. J Med Microbiol 1995;43:452-7.
117. Revankar SG, Sanche SE, Dib OP, Caceres M, Patterson TF. Effect of highly active antiretroviral therapy on recurrent oropharyngeal candidiasis in HIV-infected patients. AIDS 1998;12:2511-3.
118. Ramirez-Amador V, Esquivel-Pedraza L, Sierra-Madero J, Soto-Ramirez L, Gonzalez-Ramirez I, Anaya-Saavedra G, et al. Oral clinical markers and viral load in a prospective cohort of Mexican HIV-infected patients. AIDS 2001;15:1910-1.
119. McCarthy GM, Mackie ID, Koval J, Sandhu HS, Daley TD. Factors associated with increased frequency of HIV-related oral candidiasis. J Oral Pathol Med 1991;20:332-6.
120. Shiboski CH, Wilson CM, Greenspan D, Hilton J, Greenspan JS, Moscicki AB. HIV-related oral manifestations among adolescents in a multicenter cohort study. J Adolesc Health 2001;29(Suppl 3):109-14.
121. Galai N, Park LP, Wesch J, Visscher B, Riddler S, Margolick JB. Effect of smoking on the clinical progression of HIV-1 infection. J Acquir Immune Defic Syndr Hum Retrovirol 1997;14:451-8.
122. Schmidt-Westhausen AM, Priepke F, Bergmann FJ, Reichart PA. Decline in the rate of oral opportunistic infections following introduction of highly active antiretroviral therapy. J Oral Pathol Med 2000;29:336-41.
123. Greenspan D, Gange SJ, Phelan JA, Navazesh M, Alves ME, MacPhail LA, et al. Incidence of oral lesions in HIV-1-infected women: reduction with HAART. J Dent Res 2004;83:145-50.
124. Cassone A, Tacconelli E, De Bernardis F, Tumbarello M, Torosantucci A, Chiani P, et al. Antiretroviral therapy with protease inhibitors has an early, immune reconstitution-independent beneficial effect on Candida virulence and oral candidiasis in human immunodeficiency virus-infected subjects. J Infect Dis 2002;185:188-95.
125. Tappuni AR, Fleming GJ. The effect of antiretroviral therapy on the prevalence of oral manifestations in HIV-infected patients: a UK study. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2001;92:623-8.
126. Pomarico L, Cerqueira DF, de Araujo Soares RM, de Souza IP, de Araujo Castro GF, Socransky S, et al. Associations among the use of highly active antiretroviral therapy, oral candidiasis, oral Candida species and salivary immunoglobulin A in HIV-infected children. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2009;108:203-10.
127. Ceballos Salobrena A, Gaitan Cepeda LA, Ruesga MT, Ceballos Garcia L, Quindos G. [Prevalence of oral lesions by Candida sp.: their varieties and serotypes in a population of patients with AIDS under a highly active antiretroviral therapy]. Rev Iberoam Micol 1998;15:141-5.
128. Powderly WG, Finkelstein D, Feinberg J, Frame P, He W, van der Horst C, et al. A randomized trial comparing fluconazole with clotrimazole troches for the prevention of fungal infections in patients with advanced human immunodeficiency virus infection. NIAID AIDS Clinical Trials Group. N Engl J Med 1995;332:700-5.
129. McKinsey DS, Wheat LJ, Cloud GA, Pierce M, Black JR, Bamberger DM, et al. Itraconazole prophylaxis for fungal infections in patients with advanced human immunodeficiency virus infection: randomized, placebo-controlled, double-blind study. National Institute of Allergy and Infectious Diseases Mycoses Study Group. Clin Infect Dis 1999;28:1049-56.
130. Manfredi R, Mastroianni A, Coronado OV, Chiodo F. Fluconazole as prophylaxis against fungal infection in patients with advanced HIV infection. Arch Intern Med 1997;157:64-9.
131. Schuman P, Capps L, Peng G, Vazquez J, el-Sadr W, Goldman AI, et al. Weekly fluconazole for the prevention of mucosal candidiasis in women with HIV infection. A randomized, double-blind, placebo-controlled trial. Terry Beirn Community Programs for Clinical Research on AIDS. Ann Intern Med 1997;126:689-96.
132. Sandven P, Bjorneklett A, Maeland A. Susceptibilities of Norwegian Candida albicans strains to fluconazole: emergence of resistance. The Norwegian Yeast Study Group. Antimicrob Agents Chemother 1993;37:2443-8.
133. Goldman M, Cloud GA, Smedema M, LeMonte A, Connolly P, McKinsey DS, et al. Does long-term itraconazole prophylaxis result in in vitro azole resistance in mucosal Candida albicans isolates from persons with advanced human immunodeficiency virus infection? The National Institute of Allergy and Infectious Diseases Mycoses study group. Antimicrob Agents Chemother 2000;44:1585-7.
134. Vazquez JA, Peng G, Sobel JD, Steele-Moore L, Schuman P, Holloway W, et al. Evolution of antifungal susceptibility among Candida species isolates recovered from human immunodeficiency virus-infected women receiving fluconazole prophylaxis. Clin Infect Dis 2001;33:1069-75.